Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trevi Therapeutics reports transformative year with strong financial position

Trevi Therapeutics' strong performance in 2022, backed by positive trial results and financial stability, sets the stage for continued growth.
While facing challenges such as potential delays and increased expenses, Trevi's strategic planning and diverse opportunities position the company for success.
By leveraging its strengths in clinical development and upcoming data releases, Trevi aims to build scientific evidence and attract potential partners.
Overall, Trevi's focus on advancing its pipeline and showcasing trial results highlights its commitment to addressing unmet medical needs.

Trevi Therapeutics advances Haduvio trials, navigates regulatory challenges for growth

Trevi Therapeutics showcased progress in Haduvio's clinical development and financial stability despite a net loss.
The company faces challenges in dosing strategies, patent coverage, and regulatory hurdles but is poised for growth through strategic initiatives.

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Conference Call Participants Serge Belanger – Needham & Company Sean Kim – Jones Trading Annabel Samimy – Stifel Operator Good afternoon and welcome to the Trevi Therapeutics' Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Trevi Therapeutics, Inc. (TRVI) Q1 2023 Earnings Call Transcript

I nitiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in idiopathic pulmonary fibrosis Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update

Trevi Therapeutics (TRVI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season?

Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m.

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023

Dr. Toby Maher of the Keck School of Medicine will give oral presentations for both scientific abstracts on oral nalbuphine extended release for chronic cough in IPF NEW HAVEN, Conn. , May 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced data will be presented from two scientific abstracts on the phase 2 CANAL trial in IPF chronic cough at the ATS 2023 International Conference, organized by the American Thoracic Society, being held in Washington, D.C.

Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference

2023 Aegis Virtual Conference, May 2-4 American Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20 Yale Innovation Summit, May 31-June 1 NEW HAVEN, Conn. , April 27, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior management will attend and present at the following May 2023 investor events.

Trevi Therapeutics to Participate in Upcoming May Investor Events

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that Jennifer Good, President and Chief Executive Officer, Lisa Delfini, Chief Financial Officer, and David Clark, MD, Chief Medical Officer, will be participating in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, at 11:00 a.m. ET. Ms. Good and Ms. Delfini will also participate in investor meetings with attendees.

Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Nat Charoensook - SVB Securities Sean Kim - Jones Trading Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call.

Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript

Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

NEW HAVEN, Conn. , March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Frazier/Fenwick Winter Investor Event, March 7-10 Oppenheimer 33rd Annual Healthcare Conference, March 13-15 – Corporate presentation will be held on Monday, March 13, at 4:00 p.m. ET BIO-Europe Spring, March 20-22 NEW HAVEN, Conn.

Trevi Therapeutics to Participate in Upcoming March Conferences

Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

BIO CEO & Investor Conference, February 6-9 – Corporate presentation Tuesday, February 7, at 10:45 a.m. ET SVB Securities Global Biopharma Conference, February 13-16 – Corporate presentation Tuesday, February 14, at 11:20 a.m.

Trevi Therapeutics to Present and Participate in Upcoming February Conferences

Phoenix, Arizona--(Newsfile Corp. - January 25, 2023) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with IPF, other chronic cough indications, and for the treatment of prurigo nodularis. President and CEO of the Company, Jennifer Good, joined Stock Day host Everett Jolly.

Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast

NEW HAVEN, Conn. , Jan. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced business updates.

Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences

Biotech Showcase 2023, January 9-11 – Corporate presentation on Tuesday, January 10, at 3:00 p.m. PT 12th Annual LifeSci Partners Corporate Access Event, January 9-11 NEW HAVEN, Conn.

Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

David Clark, MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn. , Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO).

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics Q3 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.

Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript

Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Fireside chat will be held on Wednesday, November 16, 2022, from 3:35 p.m. to 4:05 p.m.

Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022

Data from full set of subjects was statistically significant for the primary efficacy endpoint (p

Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting

Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global Investors LP, revealed in a Schedule 13G filing that he entered a new position in Trevi Therapeutics Inc. ( TRVI , Financial).

News for Trevi Therapeutics Inc Stock (TRVI)